Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by SCRI Development Innovations, LLC
Sponsor:
Collaborators:
Prometheus Laboratories
Genentech
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT01048099
First received: January 12, 2010
Last updated: April 16, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)